An intact-mass LC-MS report often places an observed molecular mass beside a theoretical value and labels the sample “confirmed.” The comparison is useful, but it answers a narrower question than the word “identity” may imply.
Intact mass can show that the dominant detected species is consistent with an expected molecular mass under the method conditions. It does not automatically prove full sequence, stereochemistry, modification position, purity, or absence of low-level variants.
Why peptide spectra contain charge envelopes
Electrospray ionization can give the same peptide multiple charges. The instrument therefore records a series of mass-to-charge peaks rather than one neutral-mass peak. Software uses that charge-state envelope to calculate, or deconvolute, an estimated intact mass.
The report should include both:
- the raw or minimally processed mass-to-charge spectrum; and
- the deconvoluted mass output.
A deconvoluted number without its underlying spectrum hides whether the charge assignment was clear, whether multiple species were present, and which peaks the software included or rejected.
Average and monoisotopic mass are different conventions
Theoretical peptide mass can be calculated using average isotopic masses or the exact masses of the lightest common isotopes. For larger peptides, the instrument may not resolve a complete monoisotopic envelope, and software may report an average neutral mass.
The observed and theoretical values must use the same convention. A report should state:
- average or monoisotopic theoretical mass;
- neutral or ion mass;
- formula and exact molecular form used in the calculation;
- whether terminal groups and modifications were included;
- whether counterions, salts, or solvates were excluded or included.
A numeric difference is uninterpretable until those choices are aligned.
Start with the exact molecular form
For a modified peptide, calculate the theoretical value from the complete structure, not a base sequence copied from a database. Relevant details can include:
- N- or C-terminal modifications;
- side-chain conjugates;
- lipid or linker groups;
- disulfide bonds;
- isotopic labels;
- salt or counterion conventions;
- oxidation, deamidation, truncation, or other variants.
Two materials can share a common name while differing by a modification that changes mass and pharmacology. Conversely, two sequences can have the same nominal mass because of isobaric residues or substitutions.
Mass accuracy and resolution are not the same
Mass accuracy describes closeness of the measured value to a reference value. Resolution describes the ability to separate nearby signals. A method can report a close deconvoluted mass while failing to resolve variants that differ only slightly or appear at low abundance.
Review:
- instrument type and resolving power;
- calibration status and check results;
- acquisition mass range;
- signal intensity and charge-state coverage;
- stated mass tolerance;
- replicate agreement;
- deconvolution algorithm and parameters.
The tolerance should be justified for the instrument, analyte, and processing method rather than selected after seeing the result.
Adducts can look like extra molecular species
Sodium, potassium, solvent, buffer, water-loss, oxidation, and other adduct or variant signals can appear in peptide spectra. Some arise from the sample; others can be introduced during preparation or ionization.
The report should assign major secondary peaks when possible and distinguish:
- a chemically related variant;
- a noncovalent adduct;
- an in-source fragment;
- a charge-assignment artifact;
- background or carryover.
Simply selecting the peak closest to the expected mass is not a complete interpretation.
A mass match does not prove sequence order
Intact mass adds the masses of the molecule’s components. It generally cannot determine their order. Leucine and isoleucine are isobaric in ordinary mass analysis, and different sequences or modification placements can sometimes produce the same total mass.
Sequence support may require tandem mass spectrometry, peptide mapping, targeted fragmentation, or another orthogonal technique. Even MS/MS has coverage and ambiguity limits that should be reported.
Intact mass is not a universal purity assay
Ionization efficiency varies among compounds. Signal intensity is not automatically proportional to mass fraction. A low-level impurity can ionize strongly, while another can be suppressed or undetected. The LC portion can help separate species, but the report must describe whether the method was designed and validated for impurity measurement.
Water, counterions, many residual solvents, and inorganic components are outside the meaning of an intact peptide mass. A gross vial-content claim therefore cannot be derived from one mass match.
Report-reading checklist
- Is the sample and lot unambiguous?
- Is the exact theoretical structure shown?
- Are average and monoisotopic conventions stated?
- Are calibration and mass tolerance documented?
- Are the raw charge envelope and deconvoluted output both available?
- Are software version and deconvolution parameters reported?
- Are major secondary species assigned or investigated?
- Was a qualified reference or system-suitability material used?
- Are replicate preparations consistent?
- Is sequence or modification placement supported by an orthogonal method?
A bounded conclusion
Prefer:
The dominant detected species produced a deconvoluted intact mass consistent with the theoretical average mass of the stated molecular form within the method’s predefined tolerance. The result supports intact-mass consistency but does not by itself establish complete sequence, stereochemistry, purity, or lot quality.
This describes exactly what the evidence contributes.
Primary and authoritative sources
- FDA/ICH Q2(R2) Validation of Analytical Procedures
- ICH Q14 Analytical Procedure Development
- LC-MS bioanalysis of intact proteins and peptides
- Mass spectrometry methods at the intact-mass level
Related Serum Research pages
This guide explains analytical evidence and does not verify a specific laboratory report or lot.
Continue reading
Editorial responsibility and corrections
Published by Serum Research. Sources checked October 1, 2026. This is educational material; no independent scientific, clinical, statistical, analytical, or regulatory review is claimed. Read how we review evidence or send a correction.
For Research Use Only. Not for Human Consumption. This page does not provide instructions for medical use or establish the identity, quality, safety, or equivalence of a catalog material.